Report Interpretation

Overview

This quick note assesses Hengrui’s licensing of ex-greater China rights to its oral GLP-1/GIP candidate HRS-1596 to Novo Nordisk. Nomura considers the transaction positive because of its potential financial contribution and its validation of Hengrui’s GLP-1 research platform.

Core views

On 29 September 2026, Hengrui announced that it had out-licensed ex-greater China rights for HRS-1596 to Novo Nordisk. HRS-1596 is a GLP-1/GIP dual-receptor agonist that may support once-weekly oral dosing. Hengrui is set to receive a USD300mn upfront payment and is eligible for up to USD2.3bn in development, regulatory and commercial milestones, alongside sales royalties. The transaction is expected to close in 4Q26E. Nomura believes HRS-1596’s potential first-in-class profile was a key reason Novo Nordisk agreed to the deal. In particular, a once-weekly oral regimen could reduce dosing frequency relative to once-daily oral GLP-1 drugs. The report frames the transaction as helping Novo Nordisk catch up with Eli Lilly in an asset class that remains early stage. HRS-1596 has received approval in China to begin Phase I trials for weight management and type 2 diabetes; management expects first patient in for obesity in late 2026E and preliminary data in 2027E. The report identifies this as Hengrui’s second out-licensing deal year to date and its fourth out-licensed GLP-1 candidate. Nomura expects the USD300mn upfront payment, if recognized in FY27F, to support its CNY3.5bn collaboration-revenue forecast. If recognized in 4Q26F, it would exceed Nomura’s existing CNY3.4bn estimate. Beyond direct financial effects, Nomura argues that the agreement should improve investor sentiment by demonstrating Hengrui’s breadth of GLP-1 modalities and positioning it as a leading Chinese pharmaceutical R&D organization. This potential validation is particularly relevant after weak recent share performance: Hengrui declined 24% over the prior 60 days while the HSHCI gained 12%, with investor concerns centered on sluggish fundamentals. Nomura nevertheless maintains Buy and its HKD73.85 target price. The stock was trading at 29.5x FY26F diluted EPS of CNY1.39, while the target price is based on a DCF model using an 8.7% WACC and 5.0% terminal growth assumption.

Analysis framework

Nomura evaluates the transaction through its payment terms, the clinical and dosing potential of HRS-1596, the likely contribution to collaboration revenue, and the deal’s implications for sentiment and Hengrui’s R&D positioning. It values the stock with a discounted-cash-flow model and compares recent share performance with the HSHCI.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted-cash-flow valuation

  Nomura derives its HKD73.85 target price using a DCF model with an 8.7% WACC and 5.0% terminal growth rate.

• Industry AnalysisProduct life cycle

  Clinical-development and product-profile assessment

  The report assesses HRS-1596 through its early clinical stage, prospective once-weekly oral dosing profile, and expected timing of patient enrollment and preliminary data.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui (1276.HK; 600276.CH)

  Primary covered company; licensor of HRS-1596 to Novo Nordisk.

  Strengths

  Broad GLP-1 modalities and a transaction that Nomura views as validating its pharmaceutical R&D capabilities.

  Weaknesses

  Recent weak share performance amid concerns about sluggish fundamentals.

  Comparison

  Its shares fell 24% over 60 days while the HSHCI gained 12%; HRS-1596’s prospective weekly oral dosing differs from once-daily oral GLP-1 drugs.

  Risks

  Price cuts in the next VBP round, valuation-premium compression, and unsuccessful business-development or clinical progress.

• Novo Nordisk

  Counterparty receiving ex-greater China rights to HRS-1596.

  Strengths

  The agreement provides access to an early-stage oral GLP-1/GIP candidate with potential once-weekly dosing.

  Comparison

  Nomura views the deal as an effort to catch up with Eli Lilly in this still-early asset area.

• Eli Lilly (LLY US)

  Competitor referenced in the oral GLP-1 area.

  Comparison

  Nomura describes Novo Nordisk’s deal as intended to help it catch up with Eli Lilly.

Key data

• Upfront paymentUSD300mnPayable to Hengrui under the Novo Nordisk licensing agreement.
• Potential milestonesUp to USD2.3bnDevelopment, regulatory and commercial milestones, in addition to sales royalties.
• Expected deal closing4Q26EExpected closing timing for the licensing transaction.
• HRS-1596 clinical timingFirst patient in late 2026E; preliminary data in 2027EFor obesity; the candidate is approved in China to initiate Phase I trials for weight management and type 2 diabetes.
• Collaboration revenue forecastCNY3.5bn in FY27FNomura expects the upfront payment, if recognized in FY27F, to support this forecast; 4Q26F recognition would exceed its CNY3.4bn estimate.
• Recent share performance24% decline versus 12% HSHCI gainOver the past 60 days.
• Valuation29.5x FY26F P/E on diluted EPS of CNY1.39Reported trading valuation for Hengrui.
• DCF assumptions8.7% WACC; 5.0% terminal growthInputs supporting the HKD73.85 target price.

Impact & implications

Nomura sees the deal as both a prospective earnings support and a validation of Hengrui’s GLP-1 development capabilities. It argues that these factors could improve sentiment after the stock’s recent weakness, while maintaining its Buy rating and target price.

Risks

• Price cuts in the next round of volume-based procurement could impede achievement of the target price.
• A narrowing valuation premium could impede achievement of the target price.
• Unsuccessful business-development execution or clinical progress could impede achievement of the target price.

What to watch

• Closing of the Novo Nordisk licensing transaction, expected in 4Q26E.
• Whether the upfront payment is recognized in 4Q26F or FY27F.
• First patient enrollment for obesity in late 2026E and preliminary HRS-1596 data in 2027E.
• Progress of HRS-1596 clinical development and further business-development execution.